|June 13, 2014|
|11:37 EDT||GES, SYY, ARWR, GPI, MHFI, OPEN, EXPR, TSRA, REY||High option volume stocks|
High option volume stocks: REY OPEN URA ARWR TSRA MHFI SYY EXPR GPI GES
News For REY;OPEN;ARWR;TSRA;MHFI;SYY;EXPR;GPI;GES From The Last 14 Days
|November 25, 2015|
|11:47 EDT||GES||Guess surges after Q3 profit beats estimates|
Shares of Guess (GES), which licenses and distributes apparel and accessories, are advancing after the company's third quarter profit surpassed analysts' consensus estimates. WHAT'S NEW: Last night, Guess reported Q3 earnings per share of 15c, beating estimates of 11c, and revenue of $521M, matching the consensus forecast. In constant currency, total net revenue decreased 3.9%. Q3 retail comparable sales including e-commerce decreased 6% in U.S. dollars and 2% in constant currency. Victor Herrero, Chief Executive Officer, commented, "I am pleased to report that third quarter results were better than our expectations. Our European retail business was especially strong with a double digit comp sales increase for the quarter for the first time in five years." GUIDANCE: Looking ahead to Q4, Guess forecast EPS of 53c-62c, versus consensus of 59c. It sees Q4 net revenues to range between a decline of 1.5% and an increase of 1.5% in constant currency, compared to consensus of $662.8M. Currency headwinds are expected to negatively impact consolidated revenue growth by approximately 5.5%, for a net decline between 7.0% and 4.0%. The estimated impact on earnings per share of the currency headwinds is approximately 18c. For FY16, Guess raised the bottom end of its EPS outlook to 93c-$1.02 from 89c-$1.02, compared to consensus of 96c. FY16 revenue is forecast to decline between 1.5% and 0.5% in constant currency, versus consensus of $2.21B. Currency headwinds are expected to negatively impact consolidated revenue growth by approximately 8.0%, for a net decline between 9.5% and 8.5%. The estimated impact on FY16 earnings per share of the currency headwinds is approximately 40c. PRICE ACTION: In late morning trading, Guess rose $1.60, or about 8.2%, to $21.14 on heavy trading volume. Despite today's advance, the shares have lost approximately 7% over the past 12 months. OTHERS TO WATCH: Other companies that distribute and license apparel and accessories include PVH Corp. (PVH), Ralph Lauren (RL), Perry Ellis (PERY) and VF Corp. (VFC).
|09:24 EDT||GES||On The Fly: Pre-market Movers |
UP AFTER EARNINGS: Deere (DE), up 4.7%... TiVo (TIVO), up 4.6%... HP Enterprise (HPE), up 2.9%... Qunar (QUNR), up 2.7%... Guess (GES), up 7%. ALSO HIGHER: Aduro BioTech (ADRO), up 6.1% after confirming that all clinical trials are continuing unaltered as planned... American Capital (ACAS), up 6.9% after announcing strategic review of alternatives and expanding its share buyback program to $1B... Pandora (P), up 5.3% after reporting the opinion of the Register of Copyrights. DOWN AFTER EARNINGS: 21Vianet (VNET), down 2.3%... HP Inc. (HPQ), down 9.1%. ALSO LOWER: TerraForm Power (TERP), down 6.1% after being downgraded to Sell from Neutral at UBS... Sunedison (SUNE), down 6.6% after being downgraded to Sell from Neutral at UBS... BioMarin (BMRN), down 2.9% after FDA panel meeting about its New Drug Application for Kyndrisa.
|November 24, 2015|
|19:26 EDT||GES||On The Fly: After Hours Movers |
UP AFTER EARNINGS: Veeva Systems (VEEV), up 7.1%... Guess (GES), up 4.7%... HP Enterprise (HPE), up 2%. ALSO HIGHER: Aduro BioTech (ADRO), up 2.8% after confirming that all clinical trials are continuing unaltered as planned... Prima BioMed (PBMD), up 1.6% after filing its investor update ahead of its General Meeting. DOWN AFTER EARNINGS: HP Inc. (HPQ), down 7.4% after reporting quarterly results.
|16:19 EDT||GES||Guess now sees FY16 EPS 93c-$1.02, consensus 96c|
Sees FY16 revenue to decline between 1.5% and 0.5% in constant currency. Currency headwinds are expected to negatively impact consolidated revenue growth by approximately 8.0%, for a net decline between 9.5% and 8.5%. The estimated impact on FY16 earnings per share of the currency headwinds is approximately 40c.
|16:18 EDT||GES||Guess sees Q4 EPS 53c-62c, consensus 59c|
Subscribe for More Information
|16:17 EDT||GES||Guess reports Q3 EPS 15c, consensus 11c|
Subscribe for More Information
|15:23 EDT||GES||Notable companies reporting after market close |
Notable companies reporting after the market close, with earnings consensus, include HP Enterprise (HPE), consensus 52c... Hewlett-Packard (HPQ), consensus 45c... Veeva (VEEV), consensus 11c... Guess (GES), consensus 11c... Caleres (CAL), consensus 78c... TiVo (TIVO), consensus 8c.
|14:17 EDT||GES||Guess technical notes ahead of earnings|
The stock has been basing, with a bullish bias, since hitting fresh 52-week lows in March of this year. There is also a very large percentage of the float short at over 27%. If the news is more bullish than traders appear to be positioned for, there could be a much stronger than typical move to the upside. Resistance levels to watch from the current price of $19.82 are at $21.12, $22.39, and $23.45 which is the 52-week high. If the news is bearish, the current recovery could be disrupted. Support levels to watch as potential downside objectives would be at $18.67, $17.83, and $17.29. The 52-week low is at $16.61.
|08:51 EDT||EXPR||Express American Eagle lululemon business trends strong, says BMO Capital|
Subscribe for More Information
|November 20, 2015|
|10:49 EDT||EXPR||Abercrombie & Fitch soars after reporting upbeat Q3 earnings|
Abercrombie & Fitch (ANF) shares jumped in morning trading after the company reported better than expected quarterly earnings. WHAT'S NEW: Before the market open, Abercrombie & Fitch reported third quarter adjusted earnings per share of 48c on revenue of $878.6M. The consensus was for EPS of 22c on revenue of $864.65M. The company said that the adjusted EPS figure included year-over-year adverse effects from changes in foreign currency exchange rates amounting to roughly 13c. Commenting on the earnings, executive chairman Arthur Martinez said that the company's results "exceeded" expectations and "provide the strongest validation yet" that the retailer's initiatives are working. WHAT'S NOTABLE: On its Q3 earnings conference call, Abercrombie said that it is eyeing expansion outside of the U.S., aiming to roll out multiple new capabilities in the U.K. The company added that it saw growth in China in the past quarter and plans to add mobile enhancements in China in 2016. STREET RESEARCH: A day before Abercrombie's Q3 earnings release, Susquehanna analyst Thomas Filandro said that the retailer was "well positioned" for the holiday season, though weather and international unrest may lead to a higher degree of near-term uncertainty. Filandro said that his firm sees improved holiday performance as Abercrombie shifts focus on an improved in-store experience, growing U.S. outlets, closing underperforming stores, and evolving its merchandise assortment. The analyst reiterated a Positive rating and a $26 price target on the company's stock. After the retailer reported earnings, KeyBanc analyst Edward Yruma maintained an Overweight rating on Abercrombie's shares, saying that the company's better than expected quarter was "particularly impressive" in light of the recent weakness in the retail sector. Yruma said that the company's new brand initiatives are taking hold and that greater expense control and reduced promotional activity are improving the well-being of the business. PRICE ACTION: In morning trading, Abercrombie & Fitch rallied over 18% to $23.00. OTHERS TO WATCH: American Eagle Outfitters (AEO) was up just under 3%, Aeropostale (ARO) gained 0.75%, Tilly's (TLYS) rallied 3.4%, Urban Outfitters (URBN) jumped more than 4%, Buckle (BKE) was up just under 1%, and Express (EXPR) fell fractionally in morning trading.
|10:00 EDT||EXPR||On The Fly: Analyst Downgrade Summary|
Today's noteworthy downgrades include: Airgas (ARG) downgraded to Hold from Buy at Jefferies... Akamai (AKAM) downgraded to Sell from Neutral at Goldman... American Woodmark (AMWD) downgraded to Neutral at Baird... Autodesk (ADSK) downgraded to Sector Perform from Outperform at RBC Capital... Barclays (BCS) downgraded to Equal Weight from Overweight at Morgan Stanley... Bed Bath & Beyond (BBBY) downgraded to Hold from Buy at Cantor... CIBC (CM) downgraded to Sector Perform from Outperform at Scotia Howard Weil... Canon (CAJ) downgraded to Neutral from Outperform at Macquarie... Chart Industries (GTLS) downgraded to Neutral from Overweight at Piper Jaffray... Cloud Peak (CLD) downgraded to Sell from Buy at UBS... Cnova (CNV) downgraded to Neutral from Overweight at JPMorgan... Diana Containerships (DCIX) downgraded to Underperform at Wells Fargo... Diana Shipping (DSX) downgraded to Market Perform from Outperform at Wells Fargo... Eagle Materials (EXP) downgraded to Neutral from Buy at Goldman... El Paso Electric (EE) downgraded to Underperform from Hold at Jefferies... Express (EXPR) downgraded to Sell from Neutral at Goldman... Fidelity & Guaranty Life (FGL) downgraded to Sector Perform from Outperform at RBC Capital... Grifols (GRFS) downgraded to Hold from Buy at Berenberg... Hanmi Financial (HAFC) downgraded to Neutral from Overweight at Piper Jaffray... Hawaiian Electric (HE) downgraded to Market Perform from Outperform at Wells Fargo... K+S (KPLUF) downgraded to Underperform from Neutral at Credit Suisse... Mentor Graphics (MENT) downgraded to Hold from Buy at Needham... Nimble Storage (NMBL) downgraded to Sector Weight from Overweight at Pacific Crest... Peabody (BTU) downgraded to Sell from Neutral at UBS... PolyOne (POL) downgraded to Neutral from Accumulate at Seaport Global... Restoration Hardware (RH) downgraded to Neutral from Buy at Goldman... Sanderson Farms (SAFM) downgraded to Neutral from Buy at Sidoti... Seaspan (SSW) downgraded to Market Perform from Outperform at Wells Fargo... SunEdison (SUNE) downgraded to Neutral from Overweight at JPMorgan... Williams-Sonoma (WSM) downgraded to Buy from Conviction Buy at Goldman... Workday (WDAY) downgraded to Neutral from Outperform at Wedbush.
|November 19, 2015|
|18:57 EDT||EXPR||Express downgraded to Sell from Neutral at Goldman|
Goldman analyst Lindsay Drucker Mann downgraded Express to Sell from Neutral and lowered her price target on Express shares to $15 from $20 due to increasingly difficult year-ago comparisons and intensifying industry headwinds -- including declining mall traffic -- ahead of the holiday season.
|10:00 EDT||SYY||On The Fly: Analyst Initiation Summary|
Subscribe for More Information
|07:27 EDT||SYY||Sysco initiated with an Outperform at Wells Fargo|
Wells Fargo analyst Zachary Fadem started SYSCO Corporation with an Outperform rating and $44-$45 price target range.
|November 18, 2015|
|08:12 EDT||SYY||Sysco raises quarterly dividend to 31c per share from 30c per share|
Subscribe for More Information
|November 17, 2015|
|08:02 EDT||MHFI||McGraw Hill Financial business and EPCO sign agreement|
S&P Capital IQ and SNL, a business unit of McGraw Hill Financial together with the Eurosystem Procurement Coordination Office, or EPCO, have signed a four-year agreement for the delivery of Standard & Poor's Ratings Services' credit ratings and research. The agreement allows the central banks of the European System of Central Banks, or ESCB, as members of EPCO to access a wide range of issuer credit data through S&P Capital IQ's RatingsDirect and Xpressfeed tools, as well as through several other market data vendors.
|November 16, 2015|
|11:09 EDT||ARWR||Arrowhead says data shows ARC-520 can produce reductions of HBV antigens|
Arrowhead Research Corporation presented data from a Phase 2a clinical study at The AASLD Liver Meeting 2015 demonstrating that ARC-520, its lead drug candidate against chronic hepatitis B infection, effectively reduced HBV viral antigens derived from cccDNA. HBV surface antigen was reduced substantially with a maximum reduction of 1.9 logs and a mean maximum reduction of 1.5 logs in treatment naive e-antigen-positive patients. This direct antiviral effect was still evident 57 days after a single dose. These data strongly support advancement of ARC-520, and Arrowhead has initiated multiple studies aimed at producing a functional cure of HBV. In this presentation, Dr. Yuen and co-authors show that in the Heparc-2001 clinical study, ARC-520 in combination with entecavir achieved maximum reductions of HBsAg, HBV DNA, HBeAg, and core-related antigen of 1.9 logs, 4.3 logs, 1.7 logs, and 1.2 logs, respectively. Consistent with findings from Arrowhead's chimpanzee study, also presented at AASLD, variations in viral antigen reduction indicated that patients previously treated with chronic entecavir and patients that were treatment-naive and negative for HBeAg likely had lower levels of cccDNA derived mRNA transcripts. As such, HBeAg-positive treatment naive patients experienced a greater relative reduction in HBsAg than patients that were HBeAg-negative or treatment experienced. One transitional patient in cohort 7 was HBeAg-positive at baseline and became HBeAg-negative at days 3 to 43. This patient experienced an intermediate response initially, however HBsAg continued to trend downward through day 57, the last time-point available. ARC-520 was well tolerated with no serious adverse events, no dose limiting toxicities, no discontinuations due to medication AEs, and a modest occurrence rate of AEs that were all deemed unrelated to study drug by the principal investigator. No AE occurred more than once. There were no AEs amongst 10 patients receiving placebo. There was a low occurrence rate of abnormal laboratory tests, with no observed relationship to timing or dose.
|08:27 EDT||ARWR||Arrowhead to hold an analyst and investor reception|
Management hosts an Analyst and Investor Reception to discuss ARC-520 and key data presented at the 66th Annual Meeting of AASLD in San Francisco on November 16 at 9:30 pm. Webcast Link
|07:25 EDT||GPI||Auto retailers outlook still positive, says KeyBanc |
After conducting extensive channel checks in October, KeyBanc believes that the sales outlook of the auto retailer sector remains strong. The firm is "becoming cautiously optimistic" on the outlook for the sector's new vehicle gross profit per unit. It keeps Outperform ratings on Asbury Automotive (ABG), Lithia Motors (LAD), Penske Automotive (PAG), CarMax (KMX), and Group 1 Automotive (GPI).
|November 15, 2015|
|18:28 EDT||ARWR||Arrowhead reports data on anti-hepatitis B effects of ARC-520 in chimpanzees|
Arrowhead announced the presentation of data demonstrating that ARC-520, its drug candidate against chronic hepatitis B infection, leads to "robust, sustained anti-viral effects in chimpanzees with chronic HBV," according to the company. Arrowhead also reported a new discovery that HBV DNA integrated into the host genome is "likely an important source of HBV surface antigen production, particularly in chimps that are negative for hepatitis B e-antigen." ARC-520 led to a drop in circulating HBsAg, with the degree of HBsAg reduction correlating with HBeAg status. HBeAg-positive and negative chimps demonstrated HBsAg reductions of 96.8%-99.8% and 68.4%-87.4%, respectively, with an intermediate response in a chimp transitioning from HBeAg positive to negative. In addition, one chimp seroconverted for HBeAg during ARC-520 therapy and had a sustained virologic response with respect to HBeAg, HBV DNA, and HBsAg. This persisted off therapy and through at least 32 weeks after ARC-520 and NUC therapy was removed. A second chimp demonstrated effects consistent with immunologic reactivation. Arrowhead also found that the predominant form of liver HBV DNA differed in HBeAg-negative versus HBeAg-positive chimps. Most HBV DNA in HBeAg-positive chimps was cccDNA, while less than 5% of HBV DNA in HBeAg-negative chimps was cccDNA. In addition, HBV RNA profiles in HBeAg-negative chimps were consistent with transcripts arising from integrated DNA. "These data and others, strongly suggest that integrated DNA is likely an important source of HBsAg production in HBeAg-negative chimps," claimed the company. "Direct confirmatory data" was obtained by treating HBeAg negative chimps with a siRNA designed to target transcripts originating from integrated HBV DNA. Up to an additional 99% of HBsAg knockdown was achieved, resulting in overall relative knockdown levels similar to those observed using ARC-520 in HBeAg-positive chimps. Arrowhead said it has incorporated one of these RNAi triggers and one targeting predominantly cccDNA derived transcripts into a new complementary drug candidate, ARC-521, that is planned to be in clinical trials in 2016. The company noted it plans to present additional data at the Hep Dart conference in December demonstrating that two of four HBeAg-positive chimps exhibited signs of immune reactivation, "which is believed to be a necessary step toward achieving a functional cure of HBV."